number of therapies in development for Stargardt's. There are oral therapies. There's an oral therapy that is a deuterated vitamin A therapy that's being advanced by a different company. This approach is intended to replace natural body with a synthetic vitamin A, which resists dimerization. So I told you earlier that vitamin A dimerizes, and that's what forms these bisretinoids, these toxins that lead to retinal cell death. Well, their molecule is a form of vitamin A that doesn't dimerize, dimerizes readily. So you would actually be replacing all your natural vitamin A with this vitamin A. We're essentially sort of in the same development plateau, if you will, with this company. Again, we're both oral therapeutics, but there are niceties about our drug that their drug doesn't have. One of them is reversibility. So it'll be very difficult to come off of a synthetic vitamin A treatment when you've essentially flooded your whole body with synthetic vitamin A. Whereas with our drug, Tinlarebant is readily removed from the... As I showed you, it doesn't have a high residence time in blood, and of course, the pharmacodynamic effect is very reversible. As I showed you earlier, approximately 14 days to go from the lowest reduction of RBP4 all the way back to the baseline value. Another participant has asked, "Do we have any research partners?" We don't have research partners per se. We have KOLs and PIs who help us advance our drug and help us get the word out, but we're not currently working with any specific research partners. There is another question on the finance, but I'm afraid I can't do. But I would ask that participant to please forward your question to our CFO, Hao-Yuan. You can find his email address, probably on this forum or certainly on our website. Although, if I would have to speak to the drivers behind the nearly 4x increase in our stock price over the 5 months, I would have to say it's because of the steady stream of very positive data that's happened. Because we have done 6-month snapshots of our data. We've had data from 6 months that has been very positive. Every time we've looked, 6 months, 12 months, 18 months, and now 24 months, we continue to see very positive data. I think the market is simply responding to those positive outcomes from each of those analyses out to the end of two years. Okay, nothing is forthcoming. So, with that, I think we can close the session. I will turn it back over to the moderator.